myd88 gene mutation Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group
Sitenames

Any (1)

Phase 2 (1)

Interventional (1)

Dana-Farber Cancer Institute (1)

No (1)

No (1)

Adult (18+) (1)

cancer (1)
dana (1)
farber (1)
gener (1)
hospit (1)
institut (1)
massachusett (1)

I am/have/had

I am/have/hadbone marrow biopsy

I am/have/hadwaldenstrom's macroglobulinemia

I am/have/hadplatelet transfusion

I am/have/hadmyd88 gene mutation

I am/have/hadneutrophil count

I am/have/hadigm level

I am/have/hadplasmapheresis

I am/have/hadmeasurable disease

I am/have/hadabsolute neutrophil count

I am/have/hadserum pregnancy test

I am/have/hadcancer

added new label for I am/have/had

more

I am looking for

I am looking forvenetoclax

I am looking forgrowth factor

I am looking foribrutinib

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

bone marrow biopsy

waldenstrom's macroglobulinemia

growth factor

platelet transfusion

myd88 gene mutation

0 views
16 Feb, 2024
2 locations

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.